Taysha Gene Therapies (TSHA) Interest & Investment Income (2021 - 2026)

Taysha Gene Therapies has disclosed Interest & Investment Income across 6 years of filings, most recently posting $2.6 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $2.6 million, up 95.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (up 59.5% YoY), and the FY2025 annual result was $9.2 million, up 32.91% from the prior year.
• Interest & Investment Income came in at $2.6 million for Q1 2026 at Taysha Gene Therapies, down from $2.9 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.2 million in Q3 2025 to a low of $9000.0 in Q3 2022.
• The 5-year median for Interest & Investment Income is $1.4 million (2024), against an average of $1.3 million.
• Across the five-year window, Interest & Investment Income plunged 78.79% in 2022 and soared 12222.22% in 2023, its largest moves.
• Taysha Gene Therapies' Interest & Investment Income stood at $199000.0 in 2022, then soared by 865.33% to $1.9 million in 2023, then retreated by 11.5% to $1.7 million in 2024, then soared by 68.82% to $2.9 million in 2025, then fell by 9.9% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $2.9 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.